Comparative Pharmacology
Head-to-head clinical analysis: CYTOXAN LYOPHILIZED versus TEPYLUTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYTOXAN LYOPHILIZED versus TEPYLUTE.
CYTOXAN (LYOPHILIZED) vs TEPYLUTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyclophosphamide is an alkylating agent that cross-links DNA, inhibiting DNA replication and transcription. It also has immunosuppressive effects by suppressing B and T lymphocyte function.
Progestin that transforms endometrium from proliferative to secretory phase, inhibits gonadotropin secretion, and increases cervical mucus viscosity.
500-1000 mg/m² IV every 2-4 weeks, or 60-120 mg/m² IV daily for 2-3 days, or 500-750 mg/m² IV every 3 weeks. Oral: 50-200 mg daily as continuous therapy.
100 mg orally once daily
None Documented
None Documented
Cyclophosphamide: 4-8 hours (dose-dependent, prolonged in hepatic impairment). Active metabolites (e.g., phosphoramide mustard): 6-12 hours.
Terminal elimination half-life is 4-6 hours in healthy adults; prolonged to 10-15 hours in severe renal impairment.
Renal: 30-60% of unchanged drug and metabolites (primarily phosphoramide mustard and acrolein). Biliary/fecal: minor (<10%).
Primarily renal (70-80% unchanged) and fecal (15-20% as metabolites).
Category C
Category C
Alkylating Agent
Alkylating Agent